Fig. 1 · Structure

Documents & Downloads

Verbascoside

Cat. No. A12014 CAS 61276-17-3

PKC inhibitor

Verbascoside is isolated from Lantana camara, acts as an ATP-competitive inhibitor of PKC, with an IC50 of 25 μM, and has antitumor, anti-inflammatory and antineuropathic pain activity.

In Stock

Publications for Verbascoside

1 publication citing this product

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PKC IC50 25 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 5.81 μM Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay [PMID: 25981688]
Erythrocyte IC50 28 μM Antioxidant activity assessed as inhibition of AAPH-induced hemolysis in rat RBC after 3 hrs [PMID: 12828473]
HCT-15 IC50 2.73 μM Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay [PMID: 25981688]
HEp-2 EC50 0.8 μg/mL Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days [PMID: 9599250]
HEp-2 IC50 44 μg/mL Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 IC50 71 μg/mL Cytotoxicity against HSV2 infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 EC50 76.9 μg/mL Cytotoxicity against RSV long infected human Hep2 cells after 3 days [PMID: 9599250]
HEp-2 EC50 9.7 μg/mL Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay [PMID: 9599250]
Hepatocyte IC50 4.6 μM Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay [PMID: 20159656]
J774.A1 EC50 4.9 x 10 Cytotoxicity against mouse J774A1 macrophages grown in monolayers by MTT assay [PMID: 16309308]
L1210 IC50 13 μM Antiproliferative activity against mouse L1210 cells after 48 hrs by coulter counting analysis [PMID: 1812212]
L929 IC50 17.8 μg/mL Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay [PMID: 20159656]
SK-MEL-2 IC50 8.52 μM Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay [PMID: 25981688]
SK-OV-3 IC50 7.61 μM Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay [PMID: 25981688]

14 records · Scroll to view more

Verbascoside Research Summary

This section summarizes 4 in vitro studies of Verbascoside from 3 published references. In vitro models include BMMs; A5 metastatic cancer cells.

Verbascoside In Vitro Studies

In BMMs, pretreatment with Verbascoside at 10 µM for 2 h decreased osteoclast number by 43% compared with cells supplemented with M-CSF and RANKL. Verbascoside at 10 µM also almost completely attenuated RANKL-induced pit formation compared with cells cultured with M-CSF and RANKL; addition 4 days after RANKL stimulation suppressed osteoclast numbers without reducing pit formation. In A5 metastatic cancer cells, Verbascoside at 500 μM for 24 h suppressed MMP-2 and MMP-9 enzymatic activities. Verbascoside showed significant, dose-dependent MAO-A inhibition, with an IC50 of 3.44 ± 0.06 µM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Verbascoside reduces osteoclast numbers in BMMs

Cell-based study · BMMs [1]

BMMs pretreated with Verbascoside at 10 µM for 2 h showed a 43% decrease in osteoclast number compared with cells supplemented with M-CSF and RANKL.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the number of osteoclasts was countedosteoclast number osteoclast number decreased by 43%[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
for 2 h; for 7 days
Method
pretreated
Vehicle
phosphate-buffered saline (PBS)
Co-treatment
Other interventions in this design: M-CSF 50 ng/ml; RANKL 100 ng/ml. Compound effect isolated by the comparison: compared to cells supplemented with M-CSF and RANKL.
Methods and source locations

Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Mice, Chemicals, and Laboratory Wares (S5); Results > Acteoside Inhibits Osteoclast Formation by Macrophages in a Dose-Dependent Manner (S85, S87); Figure 1 legend (S151)

the number of osteoclasts was counted: the number of osteoclasts was counted; comparator: cells supplemented with M-CSF and RANKL — Results > Acteoside Inhibits Osteoclast Formation by Macrophages in a Dose-Dependent Manner (S87); Figure 1 legend (S151)

Verbascoside suppresses enzymatic activities in metastatic cancer cells

Cell-based study · A5 metastatic cancer cells [2]

Treatment of A5 metastatic cancer cells with Verbascoside at 500 μM for 24 h suppressed MMP-2 and MMP-9 enzymatic activities.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MMP-9 and MMP-2 enzymatic activitiesReported result After treatment with 500 μM acteoside for 24 h, acteoside suppressed the MMP-2 and MMP-9 enzymatic activities in A5 cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
500 μM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Acteoside is increasingly toxic in mouse and human cancer cells (S52); Fig. 1 legend (S95)

MMP-9 and MMP-2 enzymatic activities: MMP-9 and MMP-2 enzymatic activities; comparator: not (-) — Results > Acteoside is increasingly toxic in mouse and human cancer cells (S52); Fig. 1 legend (S95)

Dose-dependent inhibition of MAO-A

Cell-based study · MAO-A [3]

Verbascoside was evaluated in a MAO-A enzyme inhibition assay with DMSO as the control. It showed significant, dose-dependent inhibitory capacity, with an IC50 of 3.44 ± 0.06 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of enzyme inhibitionIC50 IC50 of 3.44 ± 0.06 µM[3]

Literature-Reported Treatment Conditions

Exposure duration
every 5 min for 40 min
Method
In each well
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Verbascoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.6. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 2.6.2. MAO-A Inhibition Assay (S82, S84, S85, S86); 3. Results > 3.5. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 3.5.2. MAO-A Inhibition Assay (S173)

percentage of enzyme inhibition: percentage of enzyme inhibition; comparator: 50µL of DMSO as a control — 2. Materials and Methods > 2.6. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 2.6.2. MAO-A Inhibition Assay (S85); 3. Results > 3.5. Neuroprotective Capacity. In Vitro Enzymatic Inhibition Capacity > 3.5.2. MAO-A Inhibition Assay (S173)

Treatment timing affects pit formation in BMMs

Cell-based study · BMMs [1]

A 10 µM acteoside treatment almost completely attenuated RANKL-induced pit formation by BMMs. The ability of acteoside to inhibit bone resorption depended on the timing of the treatment relative to RANKL stimulation. Acteoside (10 µM) added 4 days after RANKL stimulation did not reduce pit formation in BMMs, whereas it suppressed the number of osteoclasts formed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
pit formation was observed under an optic microscopeReported result A 10 µM acteoside treatment almost completely attenuated RANKL-induced pit formation by BMMs. The ability of acteoside to inhibit bone resorption depended on the timing of the treatment relative to RANKL stimulation. Acteoside (10 µM) added 4 days after RANKL stimulation did not reduce pit formation in BMMs, whereas it suppressed the number of osteoclasts formed.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
7 days
Method
with and without acteoside
Vehicle
phosphate-buffered saline (PBS)
Co-treatment
Other interventions in this design: M-CSF 50 ng/ml; RANKL 100 ng/ml. Compound effect isolated by the comparison: vs. cells cultured with M-CSF and RANKL.
Methods and source locations

Compound reported in the paper: Verbascoside; Compound label in the paper: Acteoside

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Mice, Chemicals, and Laboratory Wares (S5); Materials and Methods > Bone Resorption Assay (S27, S28); Results > Acteoside Inhibits Bone Resorption by Macrophages (S101, S103, S104); Figure 3 legend (S163)

pit formation was observed under an optic microscope: pit formation was observed under an optic microscope; comparator: cells cultured with M-CSF and RANKL — Materials and Methods > Bone Resorption Assay (S28); Results > Acteoside Inhibits Bone Resorption by Macrophages (S101, S103, S104)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 61276-17-3
Applications PKC inhibitor
Formula C29H36O15
Molecular Weight 624.59
Synonyms Acetoside; Kusaginin
SMILES
OC1=CC=C(/C=C/C(O[C@H]2[C@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](OCCC4=CC=C(O)C(O)=C4)O[C@@H]2CO)=O)C=C1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 92 mg/mL (147.29 mM)
Water 92 mg/mL (147.29 mM)
Ethanol 21 mg/mL (33.62 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Verbascoside Research References

  1. [1] Lee SY, Lee KS, Yi SH, et al. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. PLoS One (2013). PMID: 24324641 DOI: 10.1371/journal.pone.0080873 Source material
  2. [2] Cheimonidi C, Samara P, Polychronopoulos P, et al. Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. Redox Biol (2018). PMID: 29505920 DOI: 10.1016/j.redox.2018.02.015 Source material
  3. [3] Burgos C, Muñoz-Mingarro D, Navarro I, et al. Neuroprotective Potential of Verbascoside Isolated from Acanthus mollis L. Leaves through Its Enzymatic Inhibition and Free Radical Scavenging Ability. Antioxidants (Basel) (2020). PMID: 33266151 DOI: 10.3390/antiox9121207 Source material

Publications

1 publication citing this product

Added to your cart

View Cart Checkout
Loading...